Medically reviewed on Sep 10, 2018
(ay nid yoo la FUN jin)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Reconstituted, Intravenous [preservative free]:
Eraxis: 50 mg (1 ea); 100 mg (1 ea) [contains polysorbate 80]
Brand Names: U.S.
- Antifungal Agent, Parenteral
Noncompetitive inhibitor of 1,3-beta-D-glucan synthase resulting in reduced formation of 1,3-beta-D-glucan, an essential polysaccharide comprising 30% to 60% of Candida cell walls (absent in mammalian cells); decreased glucan content leads to osmotic instability and cellular lysis
No hepatic metabolism observed; undergoes slow chemical hydrolysis to open-ring peptide lacking antifungal activity
Feces (30%, 10% as unchanged drug); urine (<1%)
Terminal: 40-50 hours
Special Populations: Children
Concentration and exposure in children were similar to those observed in adults.
Use: Labeled Indications
Treatment of candidemia, esophageal candidiasis, and other forms of Candida infections (intra-abdominal abscess and peritonitis)
Off Label Uses
Candidiasis, intravascular infections
Based on the Infectious Diseases Society of America (IDSA) clinical practice guidelines for the management of candidiasis, anidulafungin is an effective and recommended treatment for patients with candida intravascular infections, including patients with endocarditis (native or prosthetic valve), infections of implantable cardiac devices (pacemaker, implantable cardiac defibrillator), and Candida suppurative thrombophlebitis.
Candidiasis, osteoarticular infections
Based on the Infectious Diseases Society of America (IDSA) clinical practice guidelines for the management of candidiasis, anidulafungin is an effective and recommended treatment for patients with Candida osteoarticular infections, including Candida osteomyelitis and Candida septic arthritis.
Candidiasis, chronic disseminated (hepatosplenic)
Based on the Infectious Diseases Society of America (IDSA) clinical practice guidelines for the management of candidiasis, anidulafungin is an effective and recommended treatment for patients with chronic disseminated (hepatosplenic) candidiasis.
Candidiasis empiric therapy (non-neutropenic ICU patients)
Based on the Infectious Diseases Society of America (IDSA) clinical practice guidelines for the management of candidiasis, anidulafungin is an effective and recommended agent for empiric therapy of suspected invasive candidiasis in non-neutropenic ICU patients.
Candidiasis, oropharyngeal (refractory disease)
Based on the Infectious Diseases Society of America (IDSA) clinical practice guidelines for the management of candidiasis, anidulafungin may be considered as an alternative for patients with oropharyngeal candidiasis refractory to other antifungals.
Candidiasis, prophylaxis against invasive candidiasis (high-risk ICU patients in units with a high rate of invasive candidiasis)
Based on the Infectious Diseases Society of America (IDSA) clinical practice guidelines for the management of candidiasis, anidulafungin may be considered as an alternative agent for prophylaxis against invasive candidiasis in high-risk patients in adult ICUs with a high rate of invasive candidiasis (>5%).
Hypersensitivity to anidulafungin, other echinocandins, or any component of the formulation
Candidemia, intra-abdominal or peritoneal candidiasis: IV: Initial dose: 200 mg on day 1; subsequent dosing: 100 mg daily; treatment should continue until 14 days after last positive culture. Note: IDSA Candidiasis guidelines recommend transition to fluconazole (eg, after 5 to 7 days in nonneutropenic patients) in clinically stable patients with fluconazole-susceptible isolates and negative repeat cultures (IDSA [Pappas 2016])
Candidiasis, chronic disseminated (hepatosplenic) (off-label use): IV: 200 mg on day 1; subsequent dosing: 100 mg daily for several weeks, followed by oral fluconazole therapy (IDSA [Pappas 2016])
Candidiasis, empiric therapy (suspected invasive candidiasis in nonneutropenic ICU patients) (off-label use): IV: 200 mg on day 1; subsequent dosing: 100 mg daily; treatment should continue for 14 days in patients with clinical improvement. Consider discontinuing after 4 to 5 days in patients with no clinical response (IDSA [Pappas 2016])
Candidiasis, intravascular infections (native or prosthetic valve endocarditis, infection of implantable cardiac devices, suppurative thrombophlebitis) (off-label use): IV: 200 mg daily. For native or prosthetic valve endocarditis, therapy should continue for at least 6 weeks after valve replacement surgery (longer durations in patients with abscesses or other complications); for patients with implantable cardiac devices, therapy should continue for 4 to 6 weeks after surgery (4 weeks for infections limited to generator pockets and at least 6 weeks for infections involving the wires); for suppurative thrombophlebitis, continue for at least 2 weeks after candidemia has cleared. Note: Step-down to fluconazole therapy is recommended in clinically stable patients with fluconazole-susceptible isolates and negative repeat cultures (IDSA [Pappas 2016])
Candidiasis, osteoarticular infections (osteomyelitis or septic arthritis) (alternative therapy) (off-label use): IV: 100 mg daily for at least 14 days, followed by fluconazole (IDSA [Pappas 2016])
Candidiasis, prophylaxis against invasive candidiasis (high-risk ICU patients in units with a high incidence of invasive candidiasis) (alternative therapy; off-label use): IV: Initial dose: 200 mg on day 1; subsequent doses: 100 mg daily (IDSA [Pappas 2016])
Candidiasis, esophageal: IV:
Manufacturer’s labeling: Initial dose: 100 mg on day 1; subsequent dosing: 50 mg daily; treatment should continue for a minimum of 14 days and for at least 7 days after symptom resolution
Alternate recommendations: 200 mg daily; may transition to oral fluconazole therapy once oral intake tolerable. In patients with fluconazole-refractory disease, continue anidulafungin for 14 to 21 days (IDSA [Pappas 2016])
Candidiasis, oropharyngeal (refractory disease) (alternative therapy) (off-label use): IV: Initial dose: 200 mg on day 1; subsequent dosing: 100 mg daily (IDSA [Pappas 2016])
Refer to adult dosing.
Dosing: Renal Impairment
No dosage adjustment necessary, including dialysis patients.
Dosing: Hepatic Impairment
No dosage adjustment necessary.
Aseptically add 15 mL (50 mg vial) or 30 mL (100 mg vial) of sterile water for injection to each vial. Further dilute 50 mg or 100 mg vials in 50 mL or 100 mL, respectively, of D5W or NS.
IV: For intravenous use only; infusion rate should not exceed 1.1 mg/minute (1.4 mL/minute or 84 mL/hour).
Store intact vials at 2°C to 8°C (36°F to 46°F); excursions at 25°C (77°F) are permitted for 96 hours and the vial may be returned to storage at 2°C to 8°C (36°F to 46°F). Do not freeze. The reconstituted solution can be stored for up to 24 hours at temperatures up to 25°C (77°F) prior to dilution into the infusion solution (D5W or NS). The infusion solution may be stored for up to 48 hours at temperatures up to 25°C (77°F) or stored in the freezer for at least 72 hours prior to administration.
Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. Avoid combination
Cardiovascular: Hypotension (15%), hypertension (12%), peripheral edema (11%)
Central nervous system: Insomnia (15%)
Endocrine & metabolic: Hypokalemia (≤25%), hypomagnesemia (12%)
Gastrointestinal: Nausea (7% to 24%), diarrhea (9% to 18%), vomiting (7% to 18%)
Genitourinary: Urinary tract infection (15%)
Hepatic: Increased serum alkaline phosphatase (12%)
Infection: Bacteremia (18%)
Respiratory: Dyspnea (12%)
Miscellaneous: Fever (9% to 18%)
2% to 10%:
Cardiovascular: Deep vein thrombosis (10%), chest pain (5%)
Central nervous system: Confusion (8%), headache (8%), depression (6%)
Dermatologic: Decubitus ulcer (5%)
Endocrine & metabolic: Hypoglycemia (7%), dehydration (6%), hyperglycemia (6%), hyperkalemia (6%)
Gastrointestinal: Constipation (8%), dyspepsia (7%), abdominal pain (6%), oral candidiasis (5%)
Hematologic & oncologic: Anemia (8% to 9%), leukocytosis (5% to 8%), thrombocythemia (6%)
Hepatic: Increased serum transaminases (≤5%)
Infection: Sepsis (7%)
Neuromuscular & skeletal: Back pain (5%)
Renal: Increased serum creatinine (5%)
Respiratory: Pleural effusion (10%), cough (7%), pneumonia (6%), respiratory distress (6%)
<2%, postmarketing, and/or case reports: Anaphylactic shock, anaphylaxis, angioedema, atrial fibrillation, blood coagulation disorder, blurred vision, bronchospasm, cholestasis, clostridium infection, diaphoresis, dizziness, ECG abnormality (including ECG changes – prolonged Q-T interval), erythema, eye pain, flushing, hepatic insufficiency, hepatic necrosis, hepatitis, hot flash, increased amylase, increased blood urea nitrogen, increased creatine phosphokinase, increased gamma-glutamyl transferase, increased serum bilirubin, increased serum lipase, infusion related reaction, prolonged prothrombin time, pruritus, right bundle branch block, rigors, seizure, sinus arrhythmia, skin rash, thrombocytopenia, thrombophlebitis, urticaria, ventricular premature contractions, visual disturbance
Concerns related to adverse effects:
• Anaphylactic reactions: Severe hypersensitivity reactions, including anaphylactic reactions and anaphylactic shock have been reported; immediate treatment for hypersensitivity reactions should be available. Discontinue treatment immediately if reactions occur.
• Hepatic effects: Elevated liver function tests, hepatitis, and hepatic failure have been reported; monitor for progressive hepatic impairment if increased transaminase enzymes noted.
• Infusion reactions: Infusion reactions (eg, bronchospasm, dyspnea, flushing, hypotension, pruritus, rash, urticaria) may occur; do not exceed recommended rate of infusion.
• Candidal infections: Safety and efficacy have not been established in other Candida infections (eg, endocarditis, osteomyelitis, meningitis).
Liver function tests
Adverse effects were observed in animal reproduction studies. Other agents are currently preferred for the treatment of Candida infections in pregnant women (IDSA [Pappas 2016]).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience nausea, vomiting, diarrhea, constipation, abdominal pain, back pain, or insomnia. Have patient report immediately to prescriber signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice), signs of fluid and electrolyte problems (mood changes, confusion, muscle pain or weakness, abnormal heartbeat, severe dizziness, passing out, tachycardia, increased thirst, seizures, loss of strength and energy, lack of appetite, urinary retention or change in amount of urine passed, dry mouth, dry eyes, or nausea or vomiting), signs of a urinary tract infection (hematuria, burning or painful urination, polyuria, fever, lower abdominal pain, or pelvic pain), signs of high blood sugar (confusion, fatigue, increased thirst, increased hunger, polyuria, flushing, fast breathing, or breath that smells like fruit), signs of low blood sugar (dizziness, headache, fatigue, feeling weak, shaking, tachycardia, confusion, increased hunger, or sweating), signs of DVT (edema, warmth, numbness, change in color, or pain in the extremities), confusion, depression, severe loss of strength and energy, mouth irritation, angina, coughing up blood, severe dizziness, passing out, vision changes, chills, pharyngitis, flushing, severe headache, shortness of breath, or swelling of arms or legs (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about anidulafungin
- Anidulafungin Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: echinocandins
Other brands: Eraxis